Submit
Search
Submit
Menu

  • Information

  • References

  • Contents

  • [1]F. H. Schroder, J. Hugosson, M. J. Roobol, T. L. Tammela, S. Ciatto, V. Nelen, M. Kwiatkowski, M. Lujan, H. Lilja, M. Zappa, L. J. Denis, F. Recker, A. Berenguer, L. Maattanen, C. H. Bangma, G. Aus, A. Villers, X. Rebillard, T. van der Kwast, B. G. Blijenberg, S. M. Moss, H. J. de Koning and A. Auvinen: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med, 360(13), 1320-8 (2009)

  • [2]G. L. Andriole, E. D. Crawford, R. L. Grubb, 3rd, S. S. Buys, D. Chia, T. R. Church, M. N. Fouad, E. P. Gelmann, P. A. Kvale, D. J. Reding, J. L. Weissfeld, L. A. Yokochi, B. O’Brien, J. D. Clapp, J. M. Rathmell, T. L. Riley, R. B. Hayes, B. S. Kramer, G. Izmirlian, A. B. Miller, P. F. Pinsky, P. C. Prorok, J. K. Gohagan, C. D. Berg and P. P. Team: Mortality results from a randomized prostate-cancer screening trial. N Engl J Med, 360(13), 1310-9 (2009)

  • [3]S. J. Freedland: Screening, risk assessment, and the approach to therapy in patients with prostate cancer. Cancer, 117(6), 1123-35 (2011)

  • [4]M. S. Cookson, G. Aus, A. L. Burnett, E. D. Canby-Hagino, A. V. D’Amico, R. R. Dmochowski, D. T. Eton, J. D. Forman, S. L. Goldenberg, J. Hernandez, C. S. Higano, S. R. Kraus, J. W. Moul, C. Tangen, J. B. Thrasher and I. Thompson: Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. The Journal of urology, 177(2), 540-5 (2007)

  • [5]K. Yamoah, C. Deville, N. Vapiwala, E. Spangler, C. M. Zeigler-Johnson, B. Malkowicz, D. I. Lee, M. Kattan, A. P. Dicker and T. R. Rebbeck: African American men with low-grade prostate cancer have increased disease recurrence after prostatectomy compared with Caucasian men. Urol Oncol, 33(2), 70 e15-22(2015)

  • [6]M. S. Ludwig, D. A. Kuban, S. S. Strom, X. L. Du, D. S. Lopez and J. M. Yamal: Assessing the Optimum Use of Androgen-Deprivation Therapy in High-Risk Prostate Cancer Patients Undergoing External Beam Radiation Therapy. Am J Mens Health (2015)

  • [7]J. Jones, W. Grizzle, H. Wang and C. Yates: MicroRNAs that affect prostate cancer: emphasis on prostate cancer in African Americans. Biotech Histochem, 88(7), 410-24 (2013)

  • [8]I. J. Powell and A. Bollig-Fischer: Minireview: the molecular and genomic basis for prostate cancer health disparities. Mol Endocrinol, 27(6), 879-91 (2013)

  • [9]B. F. Drake, T. E. Keane, C. M. Mosley, S. A. Adams, K. T. Elder, M. V. Modayil, J. R. Ureda and J. R. Hebert: Prostate cancer disparities in South Carolina: early detection, special programs, and descriptive epidemiology. J S C Med Assoc, 102(7), 241-9(2006)

  • [10]K. A. Cooney: Hereditary prostate cancer in African-American families. Semin Urol Oncol, 16(4), 202-6(1998)

  • [11]P. E. Li and P. S. Nelson: Prostate cancer genomics. Curr Urol Rep, 2(1), 70-8 (2001)

  • [12]W. B. Isaacs: Molecular genetics of prostate cancer. Cancer Surv, 25, 357-79(1995)

  • [13]S. C. Baca, D. Prandi, M. S. Lawrence, J. M. Mosquera, A. Romanel, Y. Drier, K. Park, N. Kitabayashi, T. Y. MacDonald, M. Ghandi, E. Van Allen, G. V. Kryukov, A. Sboner, J. P. Theurillat, T. D. Soong, E. Nickerson, D. Auclair, A. Tewari, H. Beltran, R. C. Onofrio, G. Boysen, C. Guiducci, C. E. Barbieri, K. Cibulskis, A. Sivachenko, S. L. Carter, G. Saksena, D. Voet, A. H. Ramos, W. Winckler, M. Cipicchio, K. Ardlie, P. W. Kantoff, M. F. Berger, S. B. Gabriel, T. R. Golub, M. Meyerson, E. S. Lander, O. Elemento, G. Getz, F. Demichelis, M. A. Rubin and L. A. Garraway: Punctuated evolution of prostate cancer genomes. Cell, 153(3), 666-77 (2013)

  • [14]C. E. Barbieri, S. C. Baca, M. S. Lawrence, F. Demichelis, M. Blattner, J. P. Theurillat, T. A. White, P. Stojanov, E. Van Allen, N. Stransky, E. Nickerson, S. S. Chae, G. Boysen, D. Auclair, R. C. Onofrio, K. Park, N. Kitabayashi, T. Y. MacDonald, K. Sheikh, T. Vuong, C. Guiducci, K. Cibulskis, A. Sivachenko, S. L. Carter, G. Saksena, D. Voet, W. M. Hussain, A. H. Ramos, W. Winckler, M. C. Redman, K. Ardlie, A. K. Tewari, J. M. Mosquera, N. Rupp, P. J. Wild, H. Moch, C. Morrissey, P. S. Nelson, P. W. Kantoff, S. B. Gabriel, T. R. Golub, M. Meyerson, E. S. Lander, G. Getz, M. A. Rubin and L. A. Garraway: Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet, 44(6), 685-9 (2012)

  • [15]s. c. m. o. Cancer Genome Atlas Research Network. Electronic address and N. Cancer Genome Atlas Research: The Molecular Taxonomy of Primary Prostate Cancer. Cell, 163(4), 1011-25 (2015)

  • [16]C. E. Barbieri, S. C. Baca, M. S. Lawrence, F. Demichelis, M. Blattner, J. P. Theurillat, T. A. White, P. Stojanov, E. Van Allen, N. Stransky, E. Nickerson, S. S. Chae, G. Boysen, D. Auclair, R. C. Onofrio, K. Park, N. Kitabayashi, T. Y. MacDonald, K. Sheikh, T. Vuong, C. Guiducci, K. Cibulskis, A. Sivachenko, S. L. Carter, G. Saksena, D. Voet, W. M. Hussain, A. H. Ramos, W. Winckler, M. C. Redman, K. Ardlie, A. K. Tewari, J. M. Mosquera, N. Rupp, P. J. Wild, H. Moch, C. Morrissey, P. S. Nelson, P. W. Kantoff, S. B. Gabriel, T. R. Golub, M. Meyerson, E. S. Lander, G. Getz, M. A. Rubin and L. A. Garraway: Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nature genetics, 44(6), 685-9 (2012)

  • [17]B. S. Taylor, N. Schultz, H. Hieronymus, A. Gopalan, Y. Xiao, B. S. Carver, V. K. Arora, P. Kaushik, E. Cerami, B. Reva, Y. Antipin, N. Mitsiades, T. Landers, I. Dolgalev, J. E. Major, M. Wilson, N. D. Socci, A. E. Lash, A. Heguy, J. A. Eastham, H. I. Scher, V. E. Reuter, P. T. Scardino, C. Sander, C. L. Sawyers and W. L. Gerald: Integrative genomic profiling of human prostate cancer. Cancer Cell, 18(1), 11-22 (2010)

  • [18]H. Hieronymus, N. Schultz, A. Gopalan, B. S. Carver, M. T. Chang, Y. Xiao, A. Heguy, K. Huberman, M. Bernstein, M. Assel, R. Murali, A. Vickers, P. T. Scardino, C. Sander, V. Reuter, B. S. Taylor and C. L. Sawyers: Copy number alteration burden predicts prostate cancer relapse. Proc Natl Acad Sci U S A, 111(30), 11139-44 (2014)

  • [19]G. Gundem, P. Van Loo, B. Kremeyer, L. B. Alexandrov, J. M. Tubio, E. Papaemmanuil, D. S. Brewer, H. M. Kallio, G. Hognas, M. Annala, K. Kivinummi, V. Goody, C. Latimer, S. O’Meara, K. J. Dawson, W. Isaacs, M. R. Emmert-Buck, M. Nykter, C. Foster, Z. Kote-Jarai, D. Easton, H. C. Whitaker, I. P. U. Group, D. E. Neal, C. S. Cooper, R. A. Eeles, T. Visakorpi, P. J. Campbell, U. McDermott, D. C. Wedge and G. S. Bova: The evolutionary history of lethal metastatic prostate cancer. Nature, 520(7547), 353-7 (2015)

  • [20]C. S. Cooper, R. Eeles, D. C. Wedge, P. Van Loo, G. Gundem, L. B. Alexandrov, B. Kremeyer, A. Butler, A. G. Lynch, N. Camacho, C. E. Massie, J. Kay, H. J. Luxton, S. Edwards, Z. Kote-Jarai, N. Dennis, S. Merson, D. Leongamornlert, J. Zamora, C. Corbishley, S. Thomas, S. Nik-Zainal, M. Ramakrishna, S. O’Meara, L. Matthews, J. Clark, R. Hurst, R. Mithen, R. G. Bristow, P. C. Boutros, M. Fraser, S. Cooke, K. Raine, D. Jones, A. Menzies, L. Stebbings, J. Hinton, J. Teague, S. McLaren, L. Mudie, C. Hardy, E. Anderson, O. Joseph, V. Goody, B. Robinson, M. Maddison, S. Gamble, C. Greenman, D. Berney, S. Hazell, N. Livni, I. P. Group, C. Fisher, C. Ogden, P. Kumar, A. Thompson, C. Woodhouse, D. Nicol, E. Mayer, T. Dudderidge, N. C. Shah, V. Gnanapragasam, T. Voet, P. Campbell, A. Futreal, D. Easton, A. Y. Warren, C. S. Foster, M. R. Stratton, H. C. Whitaker, U. McDermott, D. S. Brewer and D. E. Neal: Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat Genet, 47(4), 367-72 (2015)

  • [21]J. Sandoval and M. Esteller: Cancer epigenomics: beyond genomics. Curr Opin Genet Dev, 22(1), 50-5 (2012)

  • [22]R. Holliday: The inheritance of epigenetic defects. Science, 238(4824), 163-70 (1987)

  • [23]F. Valdes-Mora and S. J. Clark: Prostate cancer epigenetic biomarkers: next-generation technologies. Oncogene, 34(13), 1609-18 (2015)

  • [24]C. S. Cooper and C. S. Foster: Concepts of epigenetics in prostate cancer development. Br J Cancer, 100(2), 240-5 (2009)

  • [25]S. Venkatesh and J. L. Workman: Histone exchange, chromatin structure and the regulation of transcription. Nat Rev Mol Cell Biol, 16(3), 178-89 (2015)

  • [26]K. K. Lee and J. L. Workman: Histone acetyltransferase complexes: one size doesn’t fit all. Nature reviews. Molecular cell biology, 8(4), 284-95 (2007)

  • [27]H. J. Kim and S. C. Bae: Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. American journal of translational research, 3(2), 166-79(2011)

  • [28]M. Albert and K. Helin: Histone methyltransferases in cancer. Seminars in cell & developmental biology, 21(2), 209-20 (2010)

  • [29]S. M. Kooistra and K. Helin: Molecular mechanisms and potential functions of histone demethylases. Nature reviews. Molecular cell biology, 13(5), 297-311 (2012)

  • [30]M. Esteller: Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet, 8(4), 286-98 (2007)

  • [31]M. J. Campbell and B. M. Turner: Altered histone modifications in cancer. Advances in experimental medicine and biology, 754, 81-107 (2013)

  • [32]K. Chiam, C. Ricciardelli and T. Bianco-Miotto: Epigenetic biomarkers in prostate cancer: Current and future uses. Cancer Lett (2012)

  • [33]C. Jeronimo, P. J. Bastian, A. Bjartell, G. M. Carbone, J. W. Catto, S. J. Clark, R. Henrique, W. G. Nelson and S. F. Shariat: Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol, 60(4), 753-66 (2011)

  • [34]M. M. Shen and C. Abate-Shen: Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev, 24(18), 1967-2000 (2010)

  • [35]S. Varambally, S. M. Dhanasekaran, M. Zhou, T. R. Barrette, C. Kumar-Sinha, M. G. Sanda, D. Ghosh, K. J. Pienta, R. G. Sewalt, A. P. Otte, M. A. Rubin and A. M. Chinnaiyan: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature, 419(6907), 624-9 (2002)

  • [36]O. R. Saramaki, T. L. Tammela, P. M. Martikainen, R. L. Vessella and T. Visakorpi: The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Genes Chromosomes Cancer, 45(7), 639-45 (2006)

  • [37]H. Denis, M. N. Ndlovu and F. Fuks: Regulation of mammalian DNA methyltransferases: a route to new mechanisms. EMBO reports, 12(7), 647-56 (2011)

  • [38]S. Djebali, C. A. Davis, A. Merkel, A. Dobin, T. Lassmann, A. Mortazavi, A. Tanzer, J. Lagarde, W. Lin, F. Schlesinger, C. Xue, G. K. Marinov, J. Khatun, B. A. Williams, C. Zaleski, J. Rozowsky, M. Roder, F. Kokocinski, R. F. Abdelhamid, T. Alioto, I. Antoshechkin, M. T. Baer, N. S. Bar, P. Batut, K. Bell, I. Bell, S. Chakrabortty, X. Chen, J. Chrast, J. Curado, T. Derrien, J. Drenkow, E. Dumais, J. Dumais, R. Duttagupta, E. Falconnet, M. Fastuca, K. Fejes-Toth, P. Ferreira, S. Foissac, M. J. Fullwood, H. Gao, D. Gonzalez, A. Gordon, H. Gunawardena, C. Howald, S. Jha, R. Johnson, P. Kapranov, B. King, C. Kingswood, O. J. Luo, E. Park, K. Persaud, J. B. Preall, P. Ribeca, B. Risk, D. Robyr, M. Sammeth, L. Schaffer, L. H. See, A. Shahab, J. Skancke, A. M. Suzuki, H. Takahashi, H. Tilgner, D. Trout, N. Walters, H. Wang, J. Wrobel, Y. Yu, X. Ruan, Y. Hayashizaki, J. Harrow, M. Gerstein, T. Hubbard, A. Reymond, S. E. Antonarakis, G. Hannon, M. C. Giddings, Y. Ruan, B. Wold, P. Carninci, R. Guigo and T. R. Gingeras: Landscape of transcription in human cells. Nature, 489(7414), 101-8 (2012)

  • [39]B. P. Lewis, C. B. Burge and D. P. BarTel: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell, 120(1), 15-20 (2005)

  • [40]M. V. Iorio and C. M. Croce: MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO molecular medicine, 4(3), 143-59 (2012)

  • [41]J. Manikandan, J. J. Aarthi, S. D. Kumar and P. N. Pushparaj: Oncomirs: the potential role of non-coding microRNAs in understanding cancer. Bioinformation, 2(8), 330-4 (2008)

  • [42]A. Esquela-Kerscher and F. J. Slack: Oncomirs-microRNAs with a role in cancer. Nature reviews. Cancer, 6(4), 259-69 (2006)

  • [43]S. Volinia, G. A. Calin, C. G. Liu, S. Ambs, A. Cimmino, F. Petrocca, R. Visone, M. Iorio, C. Roldo, M. Ferracin, R. L. Prueitt, N. Yanaihara, G. Lanza, A. Scarpa, A. Vecchione, M. Negrini, C. C. Harris and C. M. Croce: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A, 103(7), 2257-61 (2006)

  • [44]J. Lu, G. Getz, E. A. Miska, E. Alvarez-Saavedra, J. Lamb, D. Peck, A. Sweet-Cordero, B. L. Ebert, R. H. Mak, A. A. Ferrando, J. R. Downing, T. Jacks, H. R. Horvitz and T. R. Golub: MicroRNA expression profiles classify human cancers. Nature, 435(7043), 834-8 (2005)

  • [45]T. Sun, Q. Wang, S. Balk, M. Brown, G. S. Lee and P. Kantoff: The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res, 69(8), 3356-63 (2009)

  • [46]R. Medina, S. K. Zaidi, C. G. Liu, J. L. Stein, A. J. van Wijnen, C. M. Croce and G. S. Stein: MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. Cancer research, 68(8), 2773-80 (2008)

  • [47]N. Mercatelli, V. Coppola, D. Bonci, F. Miele, A. Costantini, M. Guadagnoli, E. Bonanno, G. Muto, G. V. Frajese, R. De Maria, L. G. Spagnoli, M. G. Farace and S. A. Ciafre: The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. PLoS ONE, 3(12), e4029 (2008)

  • [48]L. Wang, H. Tang, V. Thayanithy, S. Subramanian, A. L. Oberg, J. M. Cunningham, J. R. Cerhan, C. J. Steer and S. N. Thibodeau: Gene networks and microRNAs implicated in aggressive prostate cancer. Cancer research, 69(24), 9490-7 (2009)

  • [49]J. Hao, C. Zhang, A. Zhang, K. Wang, Z. Jia, G. Wang, L. Han, C. Kang and P. Pu: miR-221/222 is the regulator of Cx43 expression in human glioblastoma cells. Oncol Rep, 27(5), 1504-10(2012)

  • [50]P. Tucci, M. Agostini, F. Grespi, E. K. Markert, A. Terrinoni, K. H. Vousden, P. A. Muller, V. Dotsch, S. Kehrloesser, B. S. Sayan, G. Giaccone, S. W. Lowe, N. Takahashi, P. Vandenabeele, R. A. Knight, A. J. Levine and G. Melino: Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 109(38), 15312-7 (2012)

  • [51]J. J. Zhao, J. Lin, H. Yang, W. Kong, L. He, X. Ma, D. Coppola and J. Q. Cheng: MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem, 283(45), 31079-86 (2008)

  • [52]T. E. Miller, K. Ghoshal, B. Ramaswamy, S. Roy, J. Datta, C. L. Shapiro, S. Jacob and S. Majumder: MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem, 283(44), 29897-903 (2008)

  • [53]D. Lin, F. Cui, Q. Bu and C. Yan: The expression and clinical significance of GTP-binding RAS-like 3 (ARHI) and microRNA 221 and 222 in prostate cancer. J Int Med Res, 39(5), 1870-5 (2011)

  • [54]S. Wach, E. Nolte, J. Szczyrba, R. Stohr, A. Hartmann, T. Orntoft, L. Dyrskjot, E. Eltze, W. Wieland, B. Keck, A. B. Ekici, F. Grasser and B. Wullich: MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening. International journal of cancer. Journal international du cancer, 130(3), 611-21 (2012)

  • [55]P. S. Mitchell, R. K. Parkin, E. M. Kroh, B. R. Fritz, S. K. Wyman, E. L. Pogosova-Agadjanyan, A. Peterson, J. Noteboom, K. C. O’Briant, A. Allen, D. W. Lin, N. Urban, C. W. Drescher, B. S. Knudsen, D. L. Stirewalt, R. Gentleman, R. L. Vessella, P. S. Nelson, D. B. Martin and M. Tewari: Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences of the United States of America, 105(30), 10513-8 (2008)

  • [56]P. S. Mitchell, R. K. Parkin, E. M. Kroh, B. R. Fritz, S. K. Wyman, E. L. Pogosova-Agadjanyan, A. Peterson, J. Noteboom, K. C. O’Briant, A. Allen, D. W. Lin, N. Urban, C. W. Drescher, B. S. Knudsen, D. L. Stirewalt, R. Gentleman, R. L. Vessella, P. S. Nelson, D. B. Martin and M. Tewari: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A, 105(30), 10513-8 (2008)

  • [57]A. W. Tong, P. Fulgham, C. Jay, P. Chen, I. Khalil, S. Liu, N. Senzer, A. C. Eklund, J. Han and J. Nemunaitis: MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther, 16(3), 206-16(2009)

  • [58]M. Ozen, C. J. Creighton, M. Ozdemir and M. Ittmann: Widespread deregulation of microRNA expression in human prostate cancer. Oncogene, 27(12), 1788-93 (2008)

  • [59]K. P. Porkka, M. J. Pfeiffer, K. K. Waltering, R. L. Vessella, T. L. Tammela and T. Visakorpi: MicroRNA expression profiling in prostate cancer. Cancer research, 67(13), 6130-5 (2007)

  • [60]Y. S. Lee, H. K. Kim, S. Chung, K. S. Kim and A. Dutta: Depletion of human micro-RNA miR-125b reveals that it is critical for the proliferation of differentiated cells but not for the down-regulation of putative targets during differentiation. J Biol Chem, 280(17), 16635-41 (2005)

  • [61]X. B. Shi, L. Xue, J. Yang, A. H. Ma, J. Zhao, M. Xu, C. G. Tepper, C. P. Evans, H. J. Kung and R. W. deVere White: An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci U S A, 104(50), 19983-8 (2007)

  • [62]X. Peng, W. Guo, T. Liu, X. Wang, X. Tu, D. Xiong, S. Chen, Y. Lai, H. Du, G. Chen, G. Liu, Y. Tang, S. Huang and X. Zou: Identification of miRs-143 and -145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT. PLoS One, 6(5), e20341 (2011)

  • [63]D. Kong, Y. Li, Z. Wang, S. Banerjee, A. Ahmad, H. R. Kim and F. H. Sarkar: miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells, 27(8), 1712-21 (2009)

  • [64]P. A. Gregory, A. G. Bert, E. L. Paterson, S. C. Barry, A. Tsykin, G. Farshid, M. A. Vadas, Y. Khew-Goodall and G. J. Goodall: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nature cell biology, 10(5), 593-601 (2008)

  • [65]M. A. Cortez, C. Bueso-Ramos, J. Ferdin, G. Lopez-Berestein, A. K. Sood and G. A. Calin: MicroRNAs in body fluids-the mix of hormones and biomarkers. Nature reviews. Clinical oncology, 8(8), 467-77 (2011)

  • [66]A. Goyal, G. H. Delves, M. Chopra, B. A. Lwaleed and A. J. Cooper: Prostate cells exposed to lycopene in vitro liberate lycopene-enriched exosomes. BJU Int, 98(4), 907-11 (2006)

  • [67]D. D. Taylor and C. Gercel-Taylor: MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol, 110(1), 13-21 (2008)

  • [68]H. Valadi, K. Ekstrom, A. Bossios, M. Sjostrand, J. J. Lee and J. O. Lotvall: Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol, 9(6), 654-9 (2007)

  • [69]T. El-Hefnawy, S. Raja, L. Kelly, W. L. Bigbee, J. M. Kirkwood, J. D. Luketich and T. E. Godfrey: Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. Clin Chem, 50(3), 564-73 (2004)

  • [70]X. Chen, Y. Ba, L. Ma, X. Cai, Y. Yin, K. Wang, J. Guo, Y. Zhang, J. Chen, X. Guo, Q. Li, X. Li, W. Wang, J. Wang, X. Jiang, Y. Xiang, C. Xu, P. Zheng, J. Zhang, R. Li, H. Zhang, X. Shang, T. Gong, G. Ning, K. Zen and C. Y. Zhang: Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res, 18(10), 997-1006 (2008)

  • [71]C. G. Liu, G. A. Calin, S. Volinia and C. M. Croce: MicroRNA expression profiling using microarrays. Nat Protoc, 3(4), 563-78 (2008)

  • [72]G. Rabinowits, C. Gercel-Taylor, J. M. Day, D. D. Taylor and G. H. Kloecker: Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer, 10(1), 42-6 (2009)

  • [73]K. R. Leite, A. Tomiyama, S. T. Reis, J. M. Sousa-Canavez, A. Sanudo, M. F. Dall’oglio, L. H. Camara-Lopes and M. Srougi: MicroRNA-100 Expression is Independently Related to Biochemical Recurrence of Prostate Cancer. J Urol, 185(3), 1118-22 (2011)

  • [74]M. D. Mattie, C. C. Benz, J. Bowers, K. Sensinger, L. Wong, G. K. Scott, V. Fedele, D. Ginzinger, R. Getts and C. Haqq: Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer, 5, 24 (2006)

  • [75]K. P. Porkka, M. J. Pfeiffer, K. K. Waltering, R. L. Vessella, T. L. Tammela and T. Visakorpi: MicroRNA expression profiling in prostate cancer. Cancer Res, 67(13), 6130-5(2007) doi:67/13/6130 (pii) 10.1.158/0008-5472.CAN-07-0533

  • [76]L. Wang, H. Tang, V. Thayanithy, S. Subramanian, A. L. Oberg, J. M. Cunningham, J. R. Cerhan, C. J. Steer and S. N. Thibodeau: Gene networks and microRNAs implicated in aggressive prostate cancer. Cancer Res, 69(24), 9490-7 (2009)

  • [77]E. S. Martens-Uzunova, S. E. Jalava, N. F. Dits, G. J. van Leenders, S. Moller, J. Trapman, C. H. Bangma, T. Litman, T. Visakorpi and G. Jenster: Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene 31(8):978-91 (2011)

  • [78]A. L. Kasinski and F. J. Slack: Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nature reviews. Cancer, 11(12), 849-64 (2011)

  • [79]P. Gandellini, M. Folini, N. Longoni, M. Pennati, M. Binda, M. Colecchia, R. Salvioni, R. Supino, R. Moretti, P. Limonta, R. Valdagni, M. G. Daidone and N. Zaffaroni: miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res, 69(6), 2287-95 (2009)

  • [80]Y. Li, T. G. VandenBoom, 2nd, D. Kong, Z. Wang, S. Ali, P. A. Philip and F. H. Sarkar: Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res, 69(16), 6704-12 (2009)

  • [81]D. Lodygin, V. Tarasov, A. Epanchintsev, C. Berking, T. Knyazeva, H. Korner, P. Knyazev, J. Diebold and H. Hermeking: Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle, 7(16), 2591-600 (2008)

  • [82]H. Hermeking: The miR-34 family in cancer and apoptosis. Cell Death Differ, 17(2), 193-9

  • [83]I. Casanova-Salas, J. Rubio-Briones, A. Fernandez-Serra and J. A. Lopez-Guerrero: miRNAs as biomarkers in prostate cancer. Clin Transl Oncol, 14(11), 803-11 (2012)

  • [84]H. L. Zhang, L. F. Yang, Y. Zhu, X. D. Yao, S. L. Zhang, B. Dai, Y. P. Zhu, Y. J. Shen, G. H. Shi and D. W. Ye: Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate, 71(3), 326-31 (2011)

  • [85]J. C. Brase, M. Johannes, T. Schlomm, M. Falth, A. Haese, T. Steuber, T. Beissbarth, R. Kuner and H. Sultmann: Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer, 128(3), 608-16 (2011)

  • [86]P. K. Singh, L. Preus, Q. Hu, L. Yan, M. D. Long, C. D. Morrison, M. Nesline, C. S. Johnson, S. Koochekpour, M. Kohli, S. Liu, D. L. Trump, L. E. Sucheston-Campbell and M. J. Campbell: Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients. Oncotarget, 5(3), 824-40 (2014)

  • [87]S. C. Theodore, M. Davis, F. Zhao, H. Wang, D. Chen, J. Rhim, W. Dean-Colomb, T. Turner, W. Ji, G. Zeng, W. Grizzle and C. Yates: MicroRNA profiling of novel African American and Caucasian Prostate Cancer cell lines reveals a reciprocal regulatory relationship of miR-152 and DNA methyltranferase 1. Oncotarget, 5(11), 3512-25 (2014)

  • [88]Y. A. Lussier, W. M. Stadler and J. L. Chen: Advantages of genomic complexity: bioinformatics opportunities in microRNA cancer signatures. J Am Med Inform Assoc, 19(2), 156-60 (2012)

  • [89]S. A. Tomlins, J. R. Day, R. J. Lonigro, D. H. Hovelson, J. Siddiqui, L. P. Kunju, R. L. Dunn, S. Meyer, P. Hodge, J. Groskopf, J. T. Wei and A. M. Chinnaiyan: Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur Urol (2015) pii: S0302-2838(15)00397-8.

  • [90]A. Young, N. Palanisamy, J. Siddiqui, D. P. Wood, J. T. Wei, A. M. Chinnaiyan, L. P. Kunju and S. A. Tomlins: Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden. Am J Clin Pathol, 138(5), 685-96 (2012)

  • [91]J. Yu, J. Yu, R. S. Mani, Q. Cao, C. J. Brenner, X. Cao, X. Wang, L. Wu, J. Li, M. Hu, Y. Gong, H. Cheng, B. Laxman, A. Vellaichamy, S. Shankar, Y. Li, S. M. Dhanasekaran, R. Morey, T. Barrette, R. J. Lonigro, S. A. Tomlins, S. Varambally, Z. S. Qin and A. M. Chinnaiyan: An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell, 17(5), 443-54 (2010)

  • [92]B. Laxman, D. S. Morris, J. Yu, J. Siddiqui, J. Cao, R. Mehra, R. J. Lonigro, A. Tsodikov, J. T. Wei, S. A. Tomlins and A. M. Chinnaiyan: A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res, 68(3), 645-9 (2008)

  • [93]F. Demichelis, K. Fall, S. Perner, O. Andren, F. Schmidt, S. R. Setlur, Y. Hoshida, J. M. Mosquera, Y. Pawitan, C. Lee, H. O. Adami, L. A. Mucci, P. W. Kantoff, S. O. Andersson, A. M. Chinnaiyan, J. E. Johansson and M. A. Rubin: TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene, 26(31), 4596-9 (2007)

  • [94]S. A. Tomlins, D. R. Rhodes, S. Perner, S. M. Dhanasekaran, R. Mehra, X. W. Sun, S. Varambally, X. Cao, J. Tchinda, R. Kuefer, C. Lee, J. E. Montie, R. B. Shah, K. J. Pienta, M. A. Rubin and A. M. Chinnaiyan: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science, 310(5748), 644-8 (2005)

  • [95]M. H. Vaarala, K. Porvari, A. Kyllonen, O. Lukkarinen and P. Vihko: The TMPRSS2 gene encoding transmembrane serine protease is overexpressed in a majority of prostate cancer patients: detection of mutated TMPRSS2 form in a case of aggressive disease. Int J Cancer, 94(5), 705-10 (2001)

  • [96]J. M. Lubieniecka, M. K. Cheteri, J. L. Stanford and E. A. Ostrander: Met160Val polymorphism in the TRMPSS2 gene and risk of prostate cancer in a population-based case-control study. Prostate, 59(4), 357-9 (2004)

  • [97]J. Farrell, D. Young, Y. Chen, J. Cullen, I. L. Rosner, J. Kagan, S. Srivastava, L. D. Mc, I. A. Sesterhenn, S. Srivastava and G. Petrovics: Predominance of ERG-negative high-grade prostate cancers in African American men. Mol Clin Oncol, 2(6), 982-986 (2014)

  • [98]J. St John, K. Powell, M. K. Conley-Lacomb and S. R. Chinni: TMPRSS2-ERG Fusion Gene Expression in Prostate Tumor Cells and Its Clinical and Biological Significance in Prostate Cancer Progression. J Cancer Sci Ther, 4(4), 94-101 (2012)

  • [99]W. Ma, K. Diep, H. A. Fritsche, N. Shore and M. Albitar: Diagnostic and prognostic scoring system for prostate cancer using urine and plasma biomarkers. Genet Test Mol Biomarkers, 18(3), 156-63 (2014)

  • [100]S. Dijkstra, I. L. Birker, F. P. Smit, G. H. Leyten, T. M. de Reijke, I. M. van Oort, P. F. Mulders, S. A. Jannink and J. A. Schalken: Prostate cancer biomarker profiles in urinary sediments and exosomes. J Urol, 191(4), 1132-8 (2014)

  • [101]D. W. Lin, L. F. Newcomb, E. C. Brown, J. D. Brooks, P. R. Carroll, Z. Feng, M. E. Gleave, R. S. Lance, M. G. Sanda, I. M. Thompson, J. T. Wei, P. S. Nelson and I. Canary Prostate Active Surveillance Study: Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res, 19(9), 2442-50 (2013)

  • [102]K. Park, J. T. Dalton, R. Narayanan, C. E. Barbieri, M. L. Hancock, D. G. Bostwick, M. S. Steiner and M. A. Rubin: TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. J Clin Oncol, 32(3), 206-11 (2014)

  • [103]O. M. Casey, L. Fang, P. G. Hynes, W. G. Abou-Kheir, P. L. Martin, H. S. Tillman, G. Petrovics, H. O. Awwad, Y. Ward, R. Lake, L. Zhang and K. Kelly: TMPRSS2-driven ERG expression in vivo increases self-renewal and maintains expression in a castration resistant subpopulation. PLoS One, 7(7), e41668 (2012)

  • [104]S. R. Williamson, S. Zhang, J. L. Yao, J. Huang, A. Lopez-Beltran, S. Shen, A. O. Osunkoya, G. T. MacLennan, R. Montironi and L. Cheng: ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Mod Pathol, 24(8), 1120-7 (2011)

  • [105]Y. Li, D. Kong, Z. Wang, A. Ahmad, B. Bao, S. Padhye and F. H. Sarkar: Inactivation of AR/TMPRSS2-ERG/Wnt signaling networks attenuates the aggressive behavior of prostate cancer cells. Cancer Prev Res (Phila), 4(9), 1495-506 (2011)

  • [106]J. C. Brase, M. Johannes, H. Mannsperger, M. Falth, J. Metzger, L. A. Kacprzyk, T. Andrasiuk, S. Gade, M. Meister, H. Sirma, G. Sauter, R. Simon, T. Schlomm, T. Beissbarth, U. Korf, R. Kuner and H. Sultmann: TMPRSS2-ERG-specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-beta signaling. BMC Cancer, 11, 507 (2011)

  • [107]J. Rubio-Briones, A. Fernandez-Serra, A. Calatrava, Z. Garcia-Casado, L. Rubio, M. A. Bonillo, I. Iborra, E. Solsona and J. A. Lopez-Guerrero: Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy. J Urol, 183(5), 2054-61 (2010)

  • [108]O. R. Saramaki, A. E. Harjula, P. M. Martikainen, R. L. Vessella, T. L. Tammela and T. Visakorpi: TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res, 14(11), 3395-400 (2008)

  • [109]C. Magi-Galluzzi, T. Tsusuki, P. Elson, K. Simmerman, C. LaFargue, R. Esgueva, E. Klein, M. A. Rubin and M. Zhou: TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate, 71(5), 489-97 (2011)

  • [110]M. Taris, J. Irani, P. Blanchet, L. Multigner, X. Cathelineau and G. Fromont: ERG expression in prostate cancer: the prognostic paradox. Prostate, 74(15), 1481-7 (2014)

  • [111]S. Rawal, D. Young, M. Williams, M. Colombo, R. Krishnappa, G. Petrovics, D. G. McLeod, S. Srivastava and I. A. Sesterhenn: Low Frequency of the ERG Oncogene Alterations in Prostate Cancer Patients from India. J Cancer, 4(6), 468-72 (2013)

  • [112]C. Magi-Galluzzi, T. Tsusuki, P. Elson, K. Simmerman, C. LaFargue, R. Esgueva, E. Klein, M. A. Rubin and M. Zhou: TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate, 71(5), 489-97 (2011)

  • [113]V. N. Giri, K. Ruth, L. Hughes, R. G. Uzzo, D. Y. Chen, S. A. Boorjian, R. Viterbo and T. R. Rebbeck: Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high-risk men: effect of TMPRSS2 Met160Val. BJU Int, 107(3), 466-70 (2011)

  • [114]M. Braun, D. Goltz, Z. Shaikhibrahim, W. Vogel, D. Bohm, V. Scheble, K. Sotlar, F. Fend, S. H. Tan, A. Dobi, G. Kristiansen, N. Wernert and S. Perner: ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer--a comparative study of two monoclonal antibodies. Prostate Cancer Prostatic Dis, 15(2), 165-9 (2012)

  • [115]P. Rosen, I. A. Sesterhenn, S. A. Brassell, D. G. McLeod, S. Srivastava and A. Dobi: Clinical potential of the ERG oncoprotein in prostate cancer. Nat Rev Urol, 9(3), 131-7 (2012)

  • [116]S. M. Falzarano, M. Zhou, P. Carver, T. Tsuzuki, K. Simmerman, H. He and C. Magi-Galluzzi: ERG gene rearrangement status in prostate cancer detected by immunohistochemistry. Virchows Arch, 459(4), 441-7 (2011)

  • [117]J. Farrell, G. Petrovics, D. G. McLeod and S. Srivastava: Genetic and molecular differences in prostate carcinogenesis between African American and Caucasian American men. Int J Mol Sci, 14(8), 15510-31 (2013)

  • [118]P. Rosen, D. Pfister, D. Young, G. Petrovics, Y. Chen, J. Cullen, D. Bohm, S. Perner, A. Dobi, D. G. McLeod, I. A. Sesterhenn and S. Srivastava: Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer. Urology, 80(4), 749-53 (2012)

  • [119]K. R. Rice, Y. Chen, A. Ali, E. J. Whitman, A. Blase, M. Ibrahim, S. Elsamanoudi, S. Brassell, B. Furusato, N. Stingle, I. A. Sesterhenn, G. Petrovics, S. Miick, H. Rittenhouse, J. Groskopf, D. G. McLeod and S. Srivastava: Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer. Clin Cancer Res, 16(5), 1572-6 (2010)

  • [120]K. Yamoah, M. H. Johnson, V. Choeurng, F. A. Faisal, K. Yousefi, Z. Haddad, A. E. Ross, M. Alshalafa, R. Den, P. Lal, M. Feldman, A. P. Dicker, E. A. Klein, E. Davicioni, T. R. Rebbeck and E. M. Schaeffer: Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer. J Clin Oncol, 33(25), 2789-96 (2015)

  • [121]D. N. Martin, A. M. Starks and S. Ambs: Biological determinants of health disparities in prostate cancer. Current opinion in oncology, 25(3), 235-41 (2013)

  • [122]B. Kwabi-Addo, S. Wang, W. Chung, J. Jelinek, S. R. Patierno, B. D. Wang, R. Andrawis, N. H. Lee, V. Apprey, J. P. Issa and M. Ittmann: Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men. Clinical cancer research: an official journal of the American Association for Cancer Research, 16(14), 3539-47 (2010)

  • [123]H. Enokida, H. Shiina, S. Urakami, M. Igawa, T. Ogishima, D. Pookot, L. C. Li, Z. L. Tabatabai, M. Kawahara, M. Nakagawa, C. J. Kane, P. R. Carroll and R. Dahiya: Ethnic group-related differences in CpG hypermethylation of the GSTP1 gene promoter among African-American, Caucasian and Asian patients with prostate cancer. International journal of cancer. Journal international du cancer, 116(2), 174-81 (2005)

  • [124]K. Woodson, R. Hayes, L. Wideroff, L. Villaruz and J. Tangrea: Hypermethylation of GSTP1, CD44, and E-cadherin genes in prostate cancer among US Blacks and Whites. Prostate, 55(3), 199-205 (2003)

  • [125]B. Kwabi-Addo, S. Wang, W. Chung, J. Jelinek, S. R. Patierno, B. D. Wang, R. Andrawis, N. H. Lee, V. Apprey, J. P. Issa and M. Ittmann: Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men. Clin Cancer Res, 16(14), 3539-47 (2010)

  • [126]Y. Kobayashi, D. M. Absher, Z. G. Gulzar, S. R. Young, J. K. McKenney, D. M. Peehl, J. D. Brooks, R. M. Myers and G. Sherlock: DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res, 21(7), 1017-27 (2011)

  • [127]P. Lopez-Serra and M. Esteller: DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer. Oncogene, 31(13), 1609-22 (2012)

  • [128]A. Yaqinuddin, S. A. Qureshi, R. Qazi, S. Farooq and F. Abbas: DNMT1 silencing affects locus specific DNA methylation and increases prostate cancer derived PC3 cell invasiveness. J Urol, 182(2), 756-61 (2009)

  • [129]V. T. Ho, M. Vanneman, H. Kim, T. Sasada, Y. J. Kang, M. Pasek, C. Cutler, J. Koreth, E. Alyea, S. Sarantopoulos, J. H. Antin, J. Ritz, C. Canning, J. Kutok, M. C. Mihm, G. Dranoff and R. Soiffer: Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proc Natl Acad Sci U S A, 106(37), 15825-30 (2009)

  • [130]S. T. Borno, A. Fischer, M. Kerick, M. Falth, M. Laible, J. C. Brase, R. Kuner, A. Dahl, C. Grimm, B. Sayanjali, M. Isau, C. Rohr, A. Wunderlich, B. Timmermann, R. Claus, C. Plass, M. Graefen, R. Simon, F. Demichelis, M. A. Rubin, G. Sauter, T. Schlomm, H. Sultmann, H. Lehrach and M. R. Schweiger: Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. Cancer Discov, 2(11), 1024-35 (2012)

  • [131]C. Zhan, L. Yan, L. Wang, W. Jiang, Y. Zhang, J. Xi, L. Chen, Y. Jin, Y. Qiao, Y. Shi and Q. Wang: Identification of reference miRNAs in human tumors by TCGA miRNA-seq data. Biochem Biophys Res Commun, 453(3), 375-8 (2014)

  • [132]M. S. Cline, B. Craft, T. Swatloski, M. Goldman, S. Ma, D. Haussler and J. Zhu: Exploring TCGA Pan-Cancer data at the UCSC Cancer Genomics Browser. Sci Rep, 3, 2652 (2013)

  • [133]R. S. Huang, E. R. Gamazon, D. Ziliak, Y. Wen, H. K. Im, W. Zhang, C. Wing, S. Duan, W. K. Bleibel, N. J. Cox and M. E. Dolan: Population differences in microRNA expression and biological implications. RNA biology, 8(4), 692-701 (2011)

  • [134]G. Korkmaz, C. le Sage, K. A. Tekirdag, R. Agami and D. Gozuacik: miR-376b controls starvation and mTOR inhibition-related autophagy by targeting ATG4C and BECN1. Autophagy, 8(2), 165-76 (2012)

  • [135]L. J. Li, Q. Huang, N. Zhang, G. B. Wang and Y. H. Liu: miR-376b-5p regulates angiogenesis in cerebral ischemia. Mol Med Rep, 10(1), 527-35 (2014)

  • [136]X. Yang, L. Bemis, L. J. Su, D. Gao and T. W. Flaig: miR-125b Regulation of Androgen Receptor Signaling Via Modulation of the Receptor Complex Co-Repressor NCOR2. BioResearch open access, 1(2), 55-62 (2012)

  • [137]H. Wang, W. Liu, S. Black, O. Turner, J. M. Daniel, W. Dean-Colomb, Q. P. He, M. Davis and C. Yates: Kaiso, a transcriptional repressor, promotes cell migration and invasion of prostate cancer cells through regulation of miR-31 expression. Oncotarget (2015)

  • [138]J. Jones, H. Wang, J. Zhou, S. Hardy, T. Turner, D. Austin, Q. He, A. Wells, W. E. Grizzle and C. Yates: Nuclear Kaiso indicates aggressive prostate cancers and promotes migration and invasiveness of prostate cancer cells. Am J Pathol, 181(5), 1836-46 (2012)

  • [139]A. Formosa, A. M. Lena, E. K. Markert, S. Cortelli, R. Miano, A. Mauriello, N. Croce, J. Vandesompele, P. Mestdagh, E. Finazzi-Agro, A. J. Levine, G. Melino, S. Bernardini and E. Candi: DNA methylation silences miR-132 in prostate cancer. Oncogene, 32(1), 127-34 (2013)

  • [140]T. Huan, J. Rong, C. Liu, X. Zhang, K. Tanriverdi, R. Joehanes, B. H. Chen, J. M. Murabito, C. Yao, P. Courchesne, P. J. Munson, C. J. O’Donnell, N. Cox, A. D. Johnson, M. G. Larson, D. Levy and J. E. Freedman: Genome-wide identification of microRNA expression quantitative trait loci. Nat Commun, 6, 6601 (2015)

  • [141]M. J. Machiela and S. J. Chanock: LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics, 31(21), 3555-7 (2015)

Article Metrics

  • Information

  • Download

  • Contents

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

1 Jan 2017Review

miRNAs as drivers of TMPRSS2-ERG negative prostate tumors in African American men

Clayton Yates 1, Mark D. Long 2, Moray J. Campbell 2,*, Lara Sucheston-Campbell 3
Affiliations
Article Info

1 Department of Biology and Center for Cancer Research, Tuskegee University, Tuskegee, AL 36088, USA

2 Departments of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA

3 Cancer Prevention and Control, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA

Abstract

African Americans (AAs) who have PCa typically have more aggressive disease and make up a disproportionate number of the disease deaths, relative to European Americans (EAs). TMPRSS2 translocations, a common event in EA patients, are exploited in diagnostic and prognostic settings, whereas they are diminished in frequency in AA men. Thus, these patients with TMPRSS2 fusion-negative disease represent an under-investigated patient group. We propose that epigenetic events are a significant and alternative driver of aggressive disease in fusion-negative PCa. To reveal epigenetically governed microRNAs (miRNAs) that are enriched in fusion-negative disease and associated with aggressive in AA PCa, we leveraged both our experimental evidence and publically available data. These analyses identified 18 miRNAs that are differentially altered in fusion-negative disease, associated with DNA CpG methylation, and implicated in aggressive and AA PCas. Understanding the relationships between miRNA expression, upstream epigenetic regulation by DNA methylation, and downstream regulation of mRNA targets in fusion negative disease is imperative to understanding the biological basis of the racial health disparity in PCa.

Keywords

  • miRNA
  • DNA Methylation
  • TMPRSS2:ERG
  • Prostate Cancer
  • African American
  • Review

References